Content

Welcome to the CJU website » LOG IN

Details

Bladder irrigation after transurethral resection of superficial bladder cancer: a systematic review of the literature
University Hospitals Cleveland Medical Center, Urology Institute, Cleveland, Ohio, USA
Dec 2018 (Vol. 25, Issue 6, Pages( 9579 - 9584)
PMID: 30553282

Abstract

Text-Size + 

  • INTRODUCTION:

    The vast majority of bladder cancer is non-muscle invasive with transurethral resection (TURBT) as the gold standard for surgical treatment. There is a high recurrence of bladder cancer post surgery, which adds to the frustration in current urologic practice. Current standard of care to further reduce bladder cancer recurrence is instillation of intravesical chemotherapy (ICT), a practice that is not routinely followed. Several studies point to similar effects with normal saline or water irrigation alone. Our objective is to review the current available literature and provide practicing urologist with an alternative to ICT.

    MATERIALS AND METHODS:

    A systematic search was performed through December 2017. Peer reviewed studies, which evaluated recurrence free survival (RFS) after bladder irrigation with saline or sterile water (SW) post-TURBT were included. Outcomes were analyzed in three groups: ICT, saline and sterile water.

    RESULTS:

    Six studies out of 981, including 1515 patients, were eligible. There was no significant difference between ICT, saline and SW groups regarding to the median RFS at 1 year [ICT: 81%, IQR (77.70, -81.00), SW: 74%, IQR (63.3-74.9), saline: 76.7% IQR (76.0, 77.7), p = 0.21]. While saline irrigation showed the highest median RFS among the groups, there was no statistically significant difference between the three groups [ICT: 70%, IQR (66.25, 73.75), SW: 64.1%, IQR (63.05, 65.15), saline: 73%, IQR (66.85, 74.50), p = 0.49]. Adverse events were more frequent amongst patients in the ICT group in comparison to the saline or water groups.

    CONCLUSION:

    Saline and sterile water irrigation provide an alternative to ICT with equivalent recurrence rate and lower incidence of adverse events.

Current Issue

August 2019, Vol.26 No.4
canadian journal of urology